AI Article Synopsis
- The CAMP study is an ongoing research project aiming to assess the mid- and long-term effects of myocarditis and pericarditis following the Pfizer-BioNTech COVID-19 vaccine in patients under 21.
- It involves a cohort of at least 200 vaccinated patients and a comparison group of 100 patients with COVID-19 related myocarditis, collecting data over a 5-year span to track health outcomes and complications.
- As of October 16, 2024, the study has enrolled 273 participants, focusing on heart function, complications, and overall quality of life post-illness.
Article Abstract
Background: Minimal data are available on mid- and long-term outcomes following COVID-19 vaccine-associated myocarditis/pericarditis. The COVID Vaccine-Associated Myocarditis/Pericarditis (CAMP) study aims to characterize the mid- and long-term sequelae of myocarditis/pericarditis following administration of any Pfizer-BioNTech COVID-19 vaccine (herein referred to as COMIRNATY®). Herein we describe the rationale and design of CAMP.
Methods: This ongoing and actively enrolling multicenter observational cohort study across 32 North American pediatric cardiac centers will include at least 200 patients <21 years-old who presented ≤21 days from COMIRNATY® vaccination and meet the Centers for Disease Control and Prevention (CDC) case definition of probable or confirmed myocarditis/pericarditis or isolated pericarditis. The comparison cohort will consist of 100 patients <21 years-old with COVID-19 associated myocarditis/pericarditis, including those who meet the contemporaneous CDC case definition of multisystem inflammatory syndrome (MIS-C). The study will collect detailed hospital and follow-up data for up to 5 years following illness onset. Electrocardiograms, echocardiograms, and cardiac magnetic resonance (CMR) examinations will be interpreted in core laboratories. The primary outcomes are 1) composite of left ventricular ejection fraction <55% by echocardiogram, findings of myocarditis by original or revised Lake Louise criteria on CMR, and/or the presence of high-grade arrhythmias or conduction system disturbances at 6 months after myocarditis/pericarditis onset; 2) complications, such as death, and non-cardiac morbidities; and 3) patient-reported outcomes of global health, functional status, and quality of life. Analyses will include descriptive statistics and regression modeling.
Current Status: Still enrolling, with 273 participants currently enrolled as of 10/16/2024 (173 vaccine-associated myocarditis/pericarditis, 100 COVID-19-associated myocarditis/pericarditis) CONCLUSIONS: With long-term follow-up and core laboratories for standardized assessments of cardiac testing, the CAMP study will make important contributions to our understanding of the mid- and long-term cardiac and non-cardiac sequelae of COVID-19 vaccine-associated myocarditis/pericarditis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ahj.2024.11.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design and rationale of the COVID vaccine-associated myocarditis/pericarditis (CAMP) study.
Am Heart J
November 2024
Department of Cardiology, Harvard Medical School and Boston Children's Hospital, Boston, MA.
Article Synopsis
- The CAMP study is an ongoing research project aiming to assess the mid- and long-term effects of myocarditis and pericarditis following the Pfizer-BioNTech COVID-19 vaccine in patients under 21.
- It involves a cohort of at least 200 vaccinated patients and a comparison group of 100 patients with COVID-19 related myocarditis, collecting data over a 5-year span to track health outcomes and complications.
- As of October 16, 2024, the study has enrolled 273 participants, focusing on heart function, complications, and overall quality of life post-illness.
The impact of COVID-19 vaccination on patients with congenital heart disease in England: a case-control study.
Heart
November 2024
Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Article Synopsis
- Patients with congenital heart disease (CHD) are at higher risk for severe COVID-19 outcomes, and this study assesses how vaccination impacts their risk levels.* -
- A case-control study compared unvaccinated and vaccinated CHD patients' COVID-19 outcomes, finding that post-vaccination CHD patients had significantly lower hospitalization (0.5% vs 15.8%) and death rates (0.5% vs 4.6%).* -
- Despite the improvements after vaccination, CHD patients remained at an increased risk of hospitalization and death compared to vaccinated controls, with no indication of faster decline in vaccine efficacy or higher rates of complications.*
Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
Vaccine
April 2024
Novavax, Inc, Gaithersburg, MD, USA.
A benefit-risk assessment of NVX-CoV2373, a vaccine to prevent COVID-19, was conducted to determine if the benefits of vaccination outweigh the risks of myocarditis/pericarditis. This analysis used data on myocarditis/pericarditis cases observed in the NVX-CoV2373 clinical studies, real-world data of mRNA COVID vaccine effectiveness against predominant SARS-CoV-2 strains in early 2023, and recent COVID-19 burden of disease data from the United States. The benefits of NVX-CoV2373 vaccination were estimated as the number of COVID-19 cases, hospitalizations, and deaths prevented.
View Article and Find Full Text PDFBenefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years.
Vaccine X
August 2023
Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
Since the authorization of the Moderna mRNA COVID-19 vaccine, real-world evidence has indicated its effectiveness in preventing COVID-19 cases. However, increased cases of mRNA vaccine-associated myocarditis/pericarditis have been reported, predominantly in young adults and adolescents. The Food and Drug Administration conducted a benefit-risk assessment to inform the review of the Biologics License Application for use of the Moderna vaccine among individuals ages 18 and older.
View Article and Find Full Text PDFCardiac Adverse Events Following COVID-19 Vaccination in Patients With Prior Vaccine-Associated Myocarditis.
Fed Pract
January 2023
Mayo Clinic, Jacksonville, Florida.
Background: Limited information exists to guide shared clinical decision making on COVID-19 vaccination in persons with a prior history of vaccine-associated myocarditis, pericarditis, or myopericarditis (VAMP). The objective of this retrospective observational case series was to characterize cardiac outcomes within 30 days following receipt of 1 or more COVID-19 vaccinations during 2021 in US service members diagnosed with prior non-COVID-19 VAMP between 1998 and 2019.
Methods: As part of the collaborative public health mission with the Centers for Disease Control and Prevention for enhanced vaccine adverse events surveillance, the Defense Health Agency Immunization Healthcare Division maintains a clinical database of service members and beneficiaries referred for suspected adverse events following immunizations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!